U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07167459) titled 'Personalized SBRT in Early-Stage Peripheral NSCLC' on Sept. 04.
Brief Summary: This study aims to learn about the long-term safety and effectiveness of personalized stereotactic body radiotherapy (SBRT) in patients with early-stage peripheral non-small cell lung cancer (NSCLC). Individualized SBRT is a specialized radiation technique that delivers precise, high-dose treatment while minimizing damage to surrounding normal tissues.
The main question it aims to answer is:
Does individualized SBRT maintain local tumor control and patient survival at 3 years without significant side effects?
Patients with early-stage peripheral NSCLC...